MX2023005935A - Compuestos aromaticos que contienen boro y analogos de insulina. - Google Patents

Compuestos aromaticos que contienen boro y analogos de insulina.

Info

Publication number
MX2023005935A
MX2023005935A MX2023005935A MX2023005935A MX2023005935A MX 2023005935 A MX2023005935 A MX 2023005935A MX 2023005935 A MX2023005935 A MX 2023005935A MX 2023005935 A MX2023005935 A MX 2023005935A MX 2023005935 A MX2023005935 A MX 2023005935A
Authority
MX
Mexico
Prior art keywords
diabetes
mody
containing compounds
aromatic boron
insulin analogs
Prior art date
Application number
MX2023005935A
Other languages
English (en)
Inventor
Ryan Kelly Spencer
Jack Joseph Steele
Jingxin Liang
Mirna Ekram Anwar Shaker
Diao Chen
Sachitanand Mali
Alborz Mahdavi
Original Assignee
Protomer Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protomer Tech Inc filed Critical Protomer Tech Inc
Publication of MX2023005935A publication Critical patent/MX2023005935A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente divulgación se refiere a nuevos compuestos que incluyen uno o más grupos aromáticos que contienen boro. La presente divulgación se refiere además a composiciones farmacéuticas que contienen tales compuestos, y su uso en la prevención y el tratamiento de trastornos, tales como hiperglucemia, diabetes tipo 2, intolerancia a la glucosa, diabetes tipo 1, obesidad, síndrome metabólico X o dislipidemia, diabetes durante el embarazo, prediabetes, enfermedad de Alzheimer, diabetes MODY 1, MODY 2 o MODY 3, trastornos del estado de ánimo y trastornos psiquiátricos.
MX2023005935A 2020-11-19 2021-11-18 Compuestos aromaticos que contienen boro y analogos de insulina. MX2023005935A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063116050P 2020-11-19 2020-11-19
US202063122338P 2020-12-07 2020-12-07
US202163210968P 2021-06-15 2021-06-15
US202163249868P 2021-09-29 2021-09-29
PCT/US2021/059802 WO2022109078A1 (en) 2020-11-19 2021-11-18 Aromatic boron-containing compounds and insulin analogs

Publications (1)

Publication Number Publication Date
MX2023005935A true MX2023005935A (es) 2023-05-29

Family

ID=79024395

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005935A MX2023005935A (es) 2020-11-19 2021-11-18 Compuestos aromaticos que contienen boro y analogos de insulina.

Country Status (13)

Country Link
EP (1) EP4247429A1 (es)
JP (1) JP2024500284A (es)
KR (1) KR20230110505A (es)
AU (1) AU2021382599A1 (es)
CA (1) CA3198757A1 (es)
CO (1) CO2023006369A2 (es)
DO (1) DOP2023000097A (es)
EC (1) ECSP23036608A (es)
IL (1) IL302775A (es)
MX (1) MX2023005935A (es)
PE (1) PE20231948A1 (es)
TW (1) TW202237188A (es)
WO (1) WO2022109078A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202409070A (zh) * 2022-05-18 2024-03-01 美商普羅托莫科技公司 芳族含硼化合物及相關胰島素類似物

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US906028A (en) 1908-03-27 1908-12-08 Herbert E Jennison Adjustable foot-block for radiators.
US4421685A (en) 1980-03-27 1983-12-20 Eli Lilly And Company Process for producing an insulin
AU682061B2 (en) 1993-09-17 1997-09-18 Novo Nordisk A/S Acylated insulin
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5504188A (en) 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5547929A (en) 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
YU18596A (sh) 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
CO4750643A1 (es) 1997-06-13 1999-03-31 Lilly Co Eli Formulacion estable de la insulina que contiene l-arginina y protamina
CA2306877A1 (en) 1997-10-24 1999-05-06 Eli Lilly And Company Insoluble insulin compositions
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
EP1044016B1 (en) 1998-01-09 2005-03-16 Novo Nordisk A/S Stabilised insulin compositions
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
JP2005526009A (ja) * 2001-12-02 2005-09-02 ノボ　ノルディスク　アクティーゼルスカブ 新規グルコース依存性インスリン
US7139665B2 (en) 2002-02-27 2006-11-21 California Institute Of Technology Computational method for designing enzymes for incorporation of non natural amino acids into proteins
AU2003236201A1 (en) 2002-05-07 2003-11-11 Novo Nordisk A/S Soluble formulations comprising monomeric insulin and acylated insulin
KR20070009565A (ko) 2004-01-23 2007-01-18 캘리포니아 인스티튜트 오브 테크놀로지 조작 단백질 및 이의 제조 및 사용 방법
MXPA06008496A (es) 2004-02-02 2007-01-30 Ambrx Inc Polipeptidos de interferon humano modificados y sus usos.
ATE541934T1 (de) 2004-12-22 2012-02-15 Ambrx Inc Zusammensetzungen von aminoacyl-trna-synthetase und verwendungen davon
KR101224781B1 (ko) 2004-12-22 2013-01-21 암브룩스, 인코포레이티드 비천연적으로 코딩된 아미노산을 포함하는 인간 성장호르몬의 조제물
US20100247433A1 (en) 2005-10-14 2010-09-30 California Institute Of Technology Use of non-canonical amino acids as metabolic markers for rapidly-dividing cells
PL1999259T3 (pl) 2006-03-03 2015-01-30 California Inst Of Techn Specyficzne miejscowo wprowadzanie aminokwasów do cząsteczek
US20080096819A1 (en) 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
US7632492B2 (en) 2006-05-02 2009-12-15 Allozyne, Inc. Modified human interferon-β polypeptides
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
JP5547083B2 (ja) 2007-11-20 2014-07-09 アンブルックス，インコーポレイテッド 修飾されたインスリンポリペプチドおよびそれらの使用
US9996862B2 (en) 2012-07-23 2018-06-12 @Pay Ip Holdings Llc Point of sale email-based e-commerce
US9867869B2 (en) * 2012-12-12 2018-01-16 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment
EP3154568A4 (en) 2014-06-10 2018-01-24 California Institute of Technology Non-canonical insulins and their uses
WO2017070617A1 (en) * 2015-10-21 2017-04-27 Case Western Reserve University Diol-modified insulin analogues containing a glucose-regulated conformational switch
MA50552A (fr) * 2017-11-09 2020-09-16 Novo Nordisk As Dérivés de liaison à l'albumine sensibles au glucose
EP3781147A4 (en) * 2018-04-16 2022-04-20 University of Utah Research Foundation GLUCOSE-SENSITIVE INSULIN
KR102507156B1 (ko) * 2019-03-29 2023-03-09 노보 노르디스크 에이/에스 포도당 민감성 인슐린 유도체
US20220288213A1 (en) * 2019-07-31 2022-09-15 Thermalin Inc. Insulin analogues with glucose regulated conformational switch
JP2023520049A (ja) * 2020-03-31 2023-05-15 プロトマー・テクノロジーズ・インコーポレイテッド 隣接ジオールに対する選択的応答性のためのコンジュゲート

Also Published As

Publication number Publication date
JP2024500284A (ja) 2024-01-09
CO2023006369A2 (es) 2023-05-19
WO2022109078A1 (en) 2022-05-27
CA3198757A1 (en) 2022-05-27
TW202237188A (zh) 2022-10-01
KR20230110505A (ko) 2023-07-24
IL302775A (en) 2023-07-01
DOP2023000097A (es) 2023-09-29
PE20231948A1 (es) 2023-12-05
ECSP23036608A (es) 2023-06-30
AU2021382599A1 (en) 2023-06-22
EP4247429A1 (en) 2023-09-27

Similar Documents

Publication Publication Date Title
PH12018500767A1 (en) Pharmaceutical composition, methods for treating and uses thereof
TW200607511A (en) Use of optically pure (S,S)-reboxetine in the manufacture of a medicament for the treatment or prevention of peripheral neuropathy
MY132789A (en) Diarylcycloalkyl derivatives, process for their preparation and their use as pharmaceuticals
TW200635903A (en) Therapeutic agents
TW200531689A (en) Therapeutic agents
TW200504034A (en) Therapeutic agents
WO2003032994A3 (de) 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
HK1076815A1 (en) 1,2,3-trisubstitued aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such asdiabetes and hyperglycemia
TR200100377T2 (tr) Aß Protein üretimi inhibitörleri olarak sukinoilamino laktamlar.
GEP20074197B (en) 5ht2c receptor modulators
MXPA05010937A (es) Derivados de fenilalanina n-(1,3-tiazol-2-il)amino)carbonil)fenil)sulfonil) y compuestos relacionados para el tratamiento de diabetes.
TW200630327A (en) Substituted phenylalkanoic acids
UA81625C2 (ru) Применение ротиготина для трансепикутального лечения синдрома уставших ног
WO2004052371A3 (en) Cyclic quinoline compounds for use in mch receptor related disorders
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
KR960700054A (ko) 파킨슨씨 병 및 파킨슨 증후군의 치료에 리루졸의 이용(application of riluzole in the treatment of parkinson's disease and parkinsonian syndromes)
MX2023005935A (es) Compuestos aromaticos que contienen boro y analogos de insulina.
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
MX2017004614A (es) Preparacion compuesta, que contiene derivado novedoso de acido 3-(4-(benciloxi)fenil)hex-4-inoico y otro ingrediente activo, para prevenir o tratar enfermedades metabolicas.
EP4233913A3 (en) Improved bromocriptine formulations
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
MX2022014309A (es) Compuestos de insulina acilada de accion temporal prolongada.
TW200509933A (en) Therapeutic agents
TW200734324A (en) Therapeutic agents
MXPA03010757A (es) Derivados de carbazol y su uso para la preparacion de composiciones farmaceuticas para el tratamiento de enfermedades relacionadas con npy.